Liposomes can both enhance or reduce drugs penetration through the skin

Peralta, Ma. Florencia; Guzmán, María Laura; Perez, Ana Paula; Apezteguia, Gustavo Alberto; Formica, María Lina; Romero, Eder Lilia; Olivera, Marı́a Eugenia; Carrer, Dolores C.

doi:10.1038/s41598-018-31693-y

Cited by 78 publications

(54 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Liposomal lipids can penetrate until 20 µm reaching the viable epidermis in greater amount than the whole liposomes per se (Peralta et al, 2018). Only liposomes containing dioleoylphophatidylethanolamine (DOPE) as lipid were able to penetrate into deeper stratum corneum (Lasch, 1992).…”

Section: Transferosomes: Versatile and Flexible Nano-vesicular Carriersmentioning

confidence: 99%

Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale

Fernández-García

Lalatsa

Statts

et al. 2020

International Journal of Pharmaceutics

168

View full text Add to dashboard Cite

Section: Transferosomes: Versatile and Flexible Nano-vesicular Carriersmentioning

confidence: 99%

Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale

Fernández-García

Lalatsa

Statts

et al. 2020

International Journal of Pharmaceutics

168

View full text Add to dashboard Cite

“…80,83 However, one of the limitations of transdermal delivery is that macromolecules and hydrophilic compounds cannot penetrate through the stratum corneum. 47 Peralta et al 84 reported that ultra-deformable liposomes (UDL), with an average particle size of 100 nm, function effectively as enhancers of skin penetration. In addition, permeation of the liposomes depends on the molecule that was incorporated; a large insoluble molecule (amphotericin B) permeates less than a small soluble molecule (indole).…”

Section: Skin Permeationmentioning

confidence: 99%

<p>Development, Characterization and Use of Liposomes as Amphipathic Transporters of Bioactive Compounds for Melanoma Treatment and Reduction of Skin Inflammation: A Review</p>

Castañeda-Reyes

Perea-Flores

Dávila-Ortíz

et al. 2020

IJN

View full text Add to dashboard Cite

The skin is the largest organ in the human body, providing a barrier to the external environment. It is composed of three layers: epidermis, dermis and hypodermis. The most external epidermis is exposed to stress factors that may lead to skin conditions such as photo-aging and skin cancer. Some treatments for skin disease utilize the incorporation of drugs or bioactive compounds into nanocarriers known as liposomes. Liposomes are membranes whose sizes range from nano to micrometers and are composed mostly of phospholipids and cholesterol, forming similar structures to cell membranes. Thus, skin treatments with liposomes have lower toxicity in comparison to traditional treatment routes such as parenteral and oral. Furthermore, addition of edge activators to the liposomes decreases the rigidity of the bilayer structure making it deformable, thereby improving skin permeability. Liposomes are composed of an aqueous core and a lipidic bilayer, which confers their amphiphilic property. Thus, they can carry hydrophobic and hydrophilic compounds, even simultaneously. Current applications of these nanocarriers are mainly in the cosmetic and pharmaceutic industries. Nevertheless, new research has revealed promising results regarding the effectiveness of liposomes for transporting bioactive compounds through the skin. Liposomes have been well studied; however, additional research is needed on the efficacy of liposomes loaded with bioactive peptides for skin delivery. The objective of this review is to provide an up-to-date description of existing techniques for the development of liposomes and their use as transporters of bioactive compounds in skin conditions such as melanoma and skin inflammation. Furthermore, to gain an understanding of the behavior of liposomes during the process of skin delivery of bioactive compounds into skin cells.

show abstract

“…However, astaxanthin has poor water-solubility, thus limiting direct application to the skin (23,24). To solve this problem, liposomal formulation improves its solubility by conjugation with phospholipid structures (25).…”

Section: Introductionmentioning

confidence: 99%

Improved Anti-Inflammatory Effects of Liposomal Astaxanthin on a Phthalic Anhydride-Induced Atopic Dermatitis Model

et al. 2020

View full text Add to dashboard Cite

Previously, we found that astaxanthin (AST) elicited an anti-inflammatory response in an experimental atopic dermatitis (AD) model. However, the use of AST was limited because of low bioavailability and solubility. We hypothesized that liposome formulation of AST could improve this. In this study, we compared the anti-inflammatory and anti-dermatotic effects of liposomal AST (L-AST) and free AST. We evaluated the effect of L-AST on a phthalic anhydride (PA)-induced animal model of AD by analyzing morphological and histopathological changes. We measured the mRNA levels of AD-related cytokines in skin tissue and immunoglobulin E concentrations in the serum. Oxidative stress and transcriptional activities of signal transducer and activator of transcription 3 (STAT3) and nuclear factor (NF)-κB were analyzed via western blotting and enzyme-linked immunosorbent assay. PA-induced dermatitis severity, epidermal thickening, and infiltration of mast cells in skin tissues were ameliorated by L-AST treatment. L-AST suppressed AD-related inflammatory mediators and the inflammation markers, inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 in PA-induced skin conditions. Oxidative stress and expression of antioxidant proteins, glutathione peroxidase-1 (GPx-1) and heme oxygenase-1 (HO-1), were recovered by L-AST treatment in skin tissues from PA-induced mice. L-AST treatment reduced transcriptional activity of STAT3 and NF-κB in PA-induced skin tissues. Our results indicate that L-AST could be more effective than free AST for AD therapy.

show abstract

Liposomes can both enhance or reduce drugs penetration through the skin

Cited by 78 publications

References 37 publications

Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale

Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale

<p>Development, Characterization and Use of Liposomes as Amphipathic Transporters of Bioactive Compounds for Melanoma Treatment and Reduction of Skin Inflammation: A Review</p>

Improved Anti-Inflammatory Effects of Liposomal Astaxanthin on a Phthalic Anhydride-Induced Atopic Dermatitis Model

Contact Info

Product

Resources

About